Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis

Background Rare pathogenic variants in cardiomyopathy (CM) genes can predispose to cardiac remodeling or fibrosis. We studied the carrier status for such variants in adults without clinical cardiovascular disease (CVD) in whom cardiac MRI (CMR)-derived measures of myocardial fibrosis were obtained in the Multi-Ethnic Study of Atherosclerosis (MESA). Objectives To identify CM-associated pathogenic variants and assess their relative prevalence in participants with extensive myocardial fibrosis by CMR. Methods MESA whole-genome sequencing data was evaluated to capture variants in CM-associated genes (n = 82). Coding variants with a frequency of <0.1% in gnomAD and 1,000 Genomes Project databases and damaging/deleterious effects based on in-silico scoring tools were assessed by ClinVar database and ACMG curation guidelines for evidence of pathogenicity. Cases were participants with high myocardial fibrosis defined as highest quartile of extracellular volume (ECV) or native T1 time in T1-mapping CMR and controls were the remainder of participants. Results A total of 1,135 MESA participants had available genetic data and phenotypic measures and were free of clinical CVD at the time of CMR. We identified 6,349 rare variants in CM-associated genes in the overall MESA population, of which six pathogenic/likely pathogenic (P/LP) variants were present in the phenotyped subpopulation. The genes harboring P/LP variants in the case group were MYH7, CRYAB, and SCN5A. The prevalence of P/LP rare variants in cases was higher than controls (5 in 420 [1.1%] vs. 1 in 715 [0.1%], p = 0.03). We identified two MYBPC3 Variants of Unknown Significance (VUS)s with borderline pathogenicity in the case group. The left ventricle (LV) volume, mass, ejection fraction (EF), and longitudinal and circumferential strain in participants with the variants were not different compared to the overall cohort. Conclusions We observed a higher prevalence of rare potentially pathogenic CM associated genetic variants in participants with significant myocardial fibrosis quantified in CMR as compared to controls without significant fibrosis. No cardiac structural or functional differences were found between participants with or without P/LP variants.

[1]  A. Lee,et al.  Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG , 2021, Circulation research.

[2]  C. Bezzina,et al.  Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies , 2021, Nature Reviews Cardiology.

[3]  Sanjiv J. Shah,et al.  Associations of Cardiac Mechanics with Exercise Capacity: The Multi-Ethnic Study of Atherosclerosis. , 2021, Journal of the American College of Cardiology.

[4]  M. Ackerman,et al.  Clinical Impact of Secondary Risk Factors in TTN-Mediated Dilated Cardiomyopathy. , 2021, Circulation. Genomic and precision medicine.

[5]  Yoonjung Kim,et al.  Effect of sarcomere and mitochondria-related mutations on myocardial fibrosis in patients with hypertrophic cardiomyopathy , 2021, Journal of Cardiovascular Magnetic Resonance.

[6]  S. Heymans,et al.  Implications of Genetic Testing in Dilated Cardiomyopathy , 2020, Circulation. Genomic and precision medicine.

[7]  S. Solomon,et al.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[8]  K. Musunuru,et al.  Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. , 2020, Circulation. Genomic and precision medicine.

[9]  A. Philippakis,et al.  Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy , 2020, Nature Communications.

[10]  J. F. Staples,et al.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy , 2020, Circulation.

[11]  N. Pereira,et al.  Genetics of dilated cardiomyopathy: practical implications for heart failure management , 2019, Nature Reviews Cardiology.

[12]  P. Munroe,et al.  Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated With Cardiac Morphogenesis and Heart Failure Development , 2019, Circulation.

[13]  Scott T. Weiss,et al.  Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations , 2019, bioRxiv.

[14]  B. Maron,et al.  Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". , 2019, Circulation.

[15]  Brian E. Cade,et al.  Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program , 2019, Nature.

[16]  D. Bluemke,et al.  Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis , 2018, European heart journal cardiovascular Imaging.

[17]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[18]  Alexandros Kouris,et al.  VarSome: the human genomic variant search engine , 2018, bioRxiv.

[19]  H. Huikuri,et al.  Primary Myocardial Fibrosis as an Alternative Phenotype Pathway of Inherited Cardiac Structural Disorders , 2018, Circulation.

[20]  D. Judge,et al.  Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[21]  Cristina Has,et al.  Faculty of 1000 evaluation for Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. , 2018 .

[22]  Tong Liu,et al.  Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure , 2017, Front. Physiol..

[23]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[24]  F. Zannad,et al.  Myocardial fibrosis: biomedical research from bench to bedside , 2017, European journal of heart failure.

[25]  S. Plein,et al.  Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review , 2016, Journal of Cardiovascular Magnetic Resonance.

[26]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[27]  David A Bluemke,et al.  Regional myocardial functional patterns: Quantitative tagged magnetic resonance imaging in an adult population free of cardiovascular risk factors: The multi‐ethnic study of atherosclerosis (MESA) , 2015, Journal of magnetic resonance imaging : JMRI.

[28]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[29]  Chia-Ying Liu,et al.  Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). , 2013, Journal of the American College of Cardiology.

[30]  N. Frangogiannis,et al.  The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.

[31]  Reza Razavi,et al.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. , 2013, JACC. Cardiovascular imaging.

[32]  Xihong Lin,et al.  Detecting Rare Variant Effects Using Extreme Phenotype Sampling in Sequencing Association Studies , 2013, Genetic epidemiology.

[33]  W. McKenna,et al.  Genetics of inherited cardiomyopathy. , 2012, European heart journal.

[34]  Pierre Croisille,et al.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.

[35]  S. Colan,et al.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.

[36]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[37]  Michael J. Zilliox,et al.  Cardiac inflammation in genetic dilated cardiomyopathy caused by MYBPC3 mutation. , 2017, Journal of molecular and cellular cardiology.

[38]  Bharath Ambale-Venkatesh,et al.  Cardiac MRI: a central prognostic tool in myocardial fibrosis , 2015, Nature Reviews Cardiology.

[39]  P. Freedson,et al.  Scientific Statement From the American Heart Association Guide to the Assessment of Physical Activity: Clinical and Research Applications: A , 2015 .